BIO’s plan for ‘securing America’s biotech century’: Trade group trying to use China as a fulcrum to advance policies to enhance U.S. competitiveness https://t.co/32cISjw9aW
China’s innovation moment sees a rise in first in class: BioCentury's Simone Fishburn & Lindsay Martin's scene setter analysis for BioCentury-BayHelix China Healthcare Summit 2026 https://t.co/xTxfxaIF5s
EMA’s CHMP backs new medicines from Hansoh, Innovent, AstraZeneca. Two out of three new drugs recommended at Committee’s November meeting are from Chinese originators. https://t.co/6cy5GrS9d0
TMC’s William McKeon on making Texas the U.S. pilot for faster trials. @TXMedCenter CEO in conversation with BioCentury's @FishburnSimone https://t.co/URfK9eFeV8
A year after Pfizer paid $10B to acquire Metsera and its metabolic programs, the pharma is now turning to Blackstone for cash to support a late-stage molecule for obesity https://t.co/cuEYEaNkgg
In BioCentury's Management Tracks: FDA's top attorney is resigning; Novo Nordisk introduced a new CFO; Haisco's head of business development is leaving; and more https://t.co/tw2bjLGQA7
Skape Bio: Designing miniproteins for GPCR pockets antibodies struggle to reach. Baker lab spinout combines de novo design with screening in human cells to develop GPCR agonists and antagonists https://t.co/inVt7tTyG0
Overton’s #FDA bid back from the brink, but HELP Committee vote uncertain. Sen. Cassidy, key to Overton’s confirmation as @US_FDA commissioner, isn’t showing his cards https://t.co/GhTuziOdUb
In BioCentury's Deals Report: Boehringer, Sino in six-program agreement for ADCs, TCEs; AbbVie gains rights to Nxera's IBD program; and more https://t.co/7bHvM7qQMc
Midterm fallout: Overton confirmation unlikely, Brenner under consideration as acting FDA commissioner, reports Washington Editor @SteveUsdin1 https://t.co/2jyuJo4R7X
In the latest move for CEO Karen Massey's aim to scale the company, argenx is buying partner Unnatural Products, gaining full control of a macrocyclic peptide program and bringing an oral therapeutics platform under its roof https://t.co/hrcxKtFEn4
Faster trials, novel biology, and looming U.S. investment curbs. Live from Shanghai, leaders from Kali, Aerska and Charles River join BioCentury This Week to discuss China’s growing role in global drug development and how COINS could reshape dealmaking. https://t.co/LPMPWLt3Ti
In BioCentury's Public Equity Report: Rezera proposes IPO terms despite NASDAQ volatility; Evommune funds a deal with a PIPE; Inovio draws cash after vaccine approval; Alnylam's buyback; and more https://t.co/SEjIeXSNws
BioCentury's analysis of emerging science from #SITC26 highlights a cluster of preclinical abstracts describing new ways to localize immune responses to tumors with cell and gene therapies https://t.co/SwhCKlbIrP